vs
Bowman Consulting Group Ltd.（BWMN）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Bowman Consulting Group Ltd.的季度营收约是再鼎医药的1.0倍（$129.0M vs $127.1M），再鼎医药同比增速更快（17.1% vs 13.9%），Bowman Consulting Group Ltd.自由现金流更多（$8.1M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 16.6%）
SLR咨询是一家私有的国际可持续发展咨询企业，在欧洲、北美洲、南美洲、大洋洲及非洲均设有办事处。公司以「推动可持续发展落地」为宗旨，凭借遍布全球的专业顾问与技术团队，携手客户共同应对全球最复杂的各类可持续发展挑战。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
BWMN vs ZLAB — 直观对比
营收规模更大
BWMN
是对方的1.0倍
$127.1M
营收增速更快
ZLAB
高出3.2%
13.9%
自由现金流更多
BWMN
多$34.8M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
16.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $129.0M | $127.1M |
| 净利润 | $2.0M | — |
| 毛利率 | 55.0% | 51.0% |
| 营业利润率 | 3.2% | -54.6% |
| 净利率 | 1.5% | — |
| 营收同比 | 13.9% | 17.1% |
| 净利润同比 | -66.7% | — |
| 每股收益（稀释后） | $0.13 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BWMNZLAB
| Q4 25 | $129.0M | $127.1M | ||
| Q3 25 | $126.0M | $115.4M | ||
| Q2 25 | $122.1M | $109.1M | ||
| Q1 25 | $112.9M | $105.7M | ||
| Q4 24 | $113.2M | $108.5M | ||
| Q3 24 | $113.9M | $101.8M | ||
| Q2 24 | $104.5M | $100.1M | ||
| Q1 24 | $94.9M | $87.1M |
净利润BWMNZLAB
| Q4 25 | $2.0M | — | ||
| Q3 25 | $6.6M | $-36.0M | ||
| Q2 25 | $6.0M | $-40.7M | ||
| Q1 25 | $-1.7M | $-48.4M | ||
| Q4 24 | $5.9M | — | ||
| Q3 24 | $771.0K | $-41.7M | ||
| Q2 24 | $-2.1M | $-80.3M | ||
| Q1 24 | $-1.6M | $-53.5M |
毛利率BWMNZLAB
| Q4 25 | 55.0% | 51.0% | ||
| Q3 25 | 53.1% | 59.5% | ||
| Q2 25 | 53.7% | 60.6% | ||
| Q1 25 | 51.4% | 63.6% | ||
| Q4 24 | 53.2% | 61.5% | ||
| Q3 24 | 52.4% | 64.1% | ||
| Q2 24 | 52.5% | 64.9% | ||
| Q1 24 | 50.6% | 61.4% |
营业利润率BWMNZLAB
| Q4 25 | 3.2% | -54.6% | ||
| Q3 25 | 4.2% | -42.3% | ||
| Q2 25 | 7.4% | -50.3% | ||
| Q1 25 | 1.0% | -53.3% | ||
| Q4 24 | 1.2% | -62.6% | ||
| Q3 24 | 0.4% | -66.6% | ||
| Q2 24 | -1.2% | -76.0% | ||
| Q1 24 | -2.8% | -80.7% |
净利率BWMNZLAB
| Q4 25 | 1.5% | — | ||
| Q3 25 | 5.3% | -31.2% | ||
| Q2 25 | 4.9% | -37.3% | ||
| Q1 25 | -1.5% | -45.8% | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | 0.7% | -40.9% | ||
| Q2 24 | -2.0% | -80.2% | ||
| Q1 24 | -1.6% | -61.4% |
每股收益（稀释后）BWMNZLAB
| Q4 25 | $0.13 | $-0.05 | ||
| Q3 25 | $0.37 | $-0.03 | ||
| Q2 25 | $0.34 | $-0.04 | ||
| Q1 25 | $-0.11 | $-0.04 | ||
| Q4 24 | $0.37 | $-0.09 | ||
| Q3 24 | $0.04 | $-0.04 | ||
| Q2 24 | $-0.13 | $-0.08 | ||
| Q1 24 | $-0.11 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.1M | $689.6M |
| 总债务越低越好 | $57.6M | — |
| 股东权益账面价值 | $261.1M | $715.5M |
| 总资产 | $579.7M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.22× | — |
8季度趋势，按日历期对齐
现金及短期投资BWMNZLAB
| Q4 25 | $11.1M | $689.6M | ||
| Q3 25 | $16.2M | $717.2M | ||
| Q2 25 | $15.5M | $732.2M | ||
| Q1 25 | $10.7M | $757.3M | ||
| Q4 24 | $6.7M | $779.7M | ||
| Q3 24 | $11.7M | $616.1M | ||
| Q2 24 | $23.1M | $630.0M | ||
| Q1 24 | $11.7M | $650.8M |
总债务BWMNZLAB
| Q4 25 | $57.6M | — | ||
| Q3 25 | $29.8M | — | ||
| Q2 25 | $32.0M | — | ||
| Q1 25 | $36.4M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $36.4M | — | ||
| Q2 24 | $38.8M | — | ||
| Q1 24 | $26.8M | — |
股东权益BWMNZLAB
| Q4 25 | $261.1M | $715.5M | ||
| Q3 25 | $261.8M | $759.9M | ||
| Q2 25 | $249.6M | $791.7M | ||
| Q1 25 | $244.1M | $810.8M | ||
| Q4 24 | $246.1M | $840.9M | ||
| Q3 24 | $243.2M | $667.7M | ||
| Q2 24 | $235.6M | $704.2M | ||
| Q1 24 | $167.3M | $762.2M |
总资产BWMNZLAB
| Q4 25 | $579.7M | $1.2B | ||
| Q3 25 | $510.2M | $1.2B | ||
| Q2 25 | $538.2M | $1.2B | ||
| Q1 25 | $528.7M | $1.2B | ||
| Q4 24 | $505.9M | $1.2B | ||
| Q3 24 | $497.0M | $985.3M | ||
| Q2 24 | $463.4M | $987.4M | ||
| Q1 24 | $420.5M | $988.4M |
负债/权益比BWMNZLAB
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.16× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $8.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | 6.3% | -21.0% |
| 资本支出强度资本支出/营收 | 0.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.76× | — |
| 过去12个月自由现金流最近4个季度 | $33.4M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流BWMNZLAB
| Q4 25 | $9.4M | $-26.0M | ||
| Q3 25 | $10.2M | $-32.0M | ||
| Q2 25 | $4.3M | $-31.0M | ||
| Q1 25 | $12.0M | $-61.7M | ||
| Q4 24 | $11.9M | $-55.8M | ||
| Q3 24 | $6.8M | $-26.8M | ||
| Q2 24 | $3.1M | $-42.2M | ||
| Q1 24 | $2.5M | $-90.1M |
自由现金流BWMNZLAB
| Q4 25 | $8.1M | $-26.7M | ||
| Q3 25 | $10.1M | $-35.0M | ||
| Q2 25 | $4.2M | $-33.9M | ||
| Q1 25 | $11.0M | $-63.2M | ||
| Q4 24 | $11.7M | $-58.4M | ||
| Q3 24 | $6.6M | $-28.2M | ||
| Q2 24 | $2.7M | $-42.9M | ||
| Q1 24 | $2.3M | $-91.1M |
自由现金流率BWMNZLAB
| Q4 25 | 6.3% | -21.0% | ||
| Q3 25 | 8.0% | -30.4% | ||
| Q2 25 | 3.4% | -31.1% | ||
| Q1 25 | 9.7% | -59.9% | ||
| Q4 24 | 10.4% | -53.8% | ||
| Q3 24 | 5.8% | -27.7% | ||
| Q2 24 | 2.6% | -42.9% | ||
| Q1 24 | 2.4% | -104.5% |
资本支出强度BWMNZLAB
| Q4 25 | 0.9% | 0.5% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.9% | 1.5% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.2% | 1.3% | ||
| Q2 24 | 0.3% | 0.7% | ||
| Q1 24 | 0.3% | 1.1% |
现金转化率BWMNZLAB
| Q4 25 | 4.76× | — | ||
| Q3 25 | 1.54× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.02× | — | ||
| Q3 24 | 8.81× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BWMN
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
